Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

BioNTech SE

Moderna

Pfizer

Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe

Will Americans Get COVID-19 Vaccine Sooner Than Europeans?

Novavax

North Korean hackers have reportedly coordinated cyberattacks against at least half a dozen drug companies working on coronavirus vaccines and treatments. A notorious hacker group that the US government has called “Kimsuky” targeted the companies in the US, the UK and South Korea in an apparent effort to steal sensitive information that North Korea could.

North Korean hackers targeted six COVID-19 drug and vaccine makers

Suspected North Korean hackers have recently tried to break into at least nine health organizations, including pharmaceutical giant Johnson & Johnson and vaccine developer Novavax Inc, revealing a broader effort to target key players in the race to develop treatments for COVID-19.

North Korea-linked hackers targeted J&J, Novavax in hunt for COVID research

CureVac B.V

Here's what you need to know about all of the leaders in the coronavirus vaccine race.

COVID Vaccine Stocks Update: Where Things Stand Now

Ambev

Aspen Technology Inc

Bruker

Cboe Global Markets

Danone SA

Con Ed

Enbridge

First American Financial

First of Long Island

Hormel Foods

Investors Title

Ohio Valley Banc

Roper Technologies

For the month, there were 13 buys including two new positions. I made the month's purchases last Friday. With the market flying high, what bargains are out there now?

IMF November Buys: The 13 Stocks Added To My Fund

Even with a late start, their vaccine might beat Moderna and Pfizer in terms of price and convenience.

Here's Why Johnson & Johnson Is Still in the Coronavirus Vaccine Race

CVS Health

Teladoc

These healthcare stocks can deliver steady growth in the coming decade as demographics suggest tailwinds for the industry. The post 4 Healthcare Stocks That Will Take Care of You appeared first on InvestorPlace.

4 Healthcare Stocks That Will Take Care of You

In the past few quarters, Johnson & Johnson struggled a bit and especially the medical devices business was affected by COVID-19. But Johnson & Johnson is a great business due to its status as dividend king, its recession-proof business and wide economic moat.

Johnson & Johnson: A Visionionary Company

Amgen

Salesforce

Goldman Sachs

Home Depot

McDonald's

Merck

Microsoft

UnitedHealth Group

Dow 30,000 is great. But a Dow Jones at 31,659 is even better — and that's where the Blue Chip average is headed in 12 months, analysts say.

9 Stocks Seen Propelling Dow To 31,662

Enterprise Products Partners

Lockheed Martin

Realty Income Corp

Shaw Communications

STAG Industrial

Exxon Mobil

From May to July, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. Those five "outstanding dividend" articles revealed 56 dividend equities. Kiplinger article titles were, 'Dividend15: Our Favorites'; 15 Super-Safe Dividends'; '7 Durable Distributions'; '13 100+ Year Dividends'; and '11 Monthly-Pay Stocks/Funds.'

Of 56 Kiplinger Outstanding Dividend Stocks, 11 Show Sweetness For December

Abbott Labs

Gilead Sciences

Inovio Pharmaceuticals

Sorrento Therapeutics Inc

Regeneron Pharmaceuticals

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here's how this affects other Covid-19-related biotech stocks. The post 7 Biotech Stocks That Are Locked in the Race for a Vaccine appeared first on InvestorPlace.

7 Biotech Stocks That Are Locked in the Race for a Vaccine

Johnson & Johnson is trading at its historic fair valuation. In today's frothy market, that makes JNJ stock quite a good blue chip holding.

Johnson & Johnson Is an Excellent Dividend Growth Stock

Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates expressed optimism on the efficacy of COVID-19 vaccines made by various drugmakers in an interview with CNN on Sunday. What Happened: The billionaire told CNN's Fareed Zakaria that while vaccines from Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) have already shown effectiveness against COVID-19 in early data, he expects similar results from AstraZeneca Plc (NYSE: AZN), Johnson & Johnson (NYSE: JNJ) and Novavax, Inc (NASDAQ: NVAX) vaccines.

Bill Gates Says AstraZeneca, Johnson & Johnson, Novavax COVID-19 Vaccines All Likely To Prove 'Very Efficacious And Safe' By February

Here are ideas for both conservative and aggressive investors.

Top COVID Vaccine Stocks to Buy Now

AbbVie

Aflac

A. O. Smith

General Dynamics

Illinois Tool Works

Lowe's

PepsiCo

Dividend Aristocrats have proven to be reliable investments, no matter what the macro environment looks like. Some of them have continued to raise the dividend at an attractive pace during this pandemic.

Dividend Growth Up To 18%: These Aristocrats Deliver During The Pandemic

The pharmaceutical industry has succeeded in doing its job in manufacturing multiple vaccines for the novel coronavirus, and it's "now in the hands" of government authorities to manage the distribution, Emily Field, head of European pharmaceutical research at Barclays, Emily Field said Friday on CNBC's "Squawk Box Europe." Price Not A Factor: Early indications suggest AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson's (NYSE: JNJ) vaccine will cost $3 to $5, while pricing for Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) could reach $40 on the high end.

Pharma Sector Did Its Job With COVID-19 Vaccine: Barclays Analyst

News for Johnson & Johnson Stock (JNJ)